Plasma Exchange versus Intravenous Immunoglobulin for Myasthenia Gravis Crisis: An Acute Hospital Cost Comparison Study
- 1 December 2011
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Clinical Neuromuscular Disease
- Vol. 13 (2) , 85-94
Abstract
Objective: To compare the short-term financial costs of treating a patient in myasthenia gravis crisis with intravenous immunoglobulin (IVIG) versus plasma exchange. Methods: An itemized comparative cost-minimization analysis of IVIG versus plasma exchange for myasthenia gravis crisis was performed. Calculations were based on each therapy's implementation cost, associated hospitalization times, and predicted cost to treat known complications. A cost superiority determination was proposed based on the total cost profile of each therapy. Results: The difference in total cost favored IVIG over plasma exchange with an average savings of $22,326 per patient. Sensitivity analysis demonstrated that overall costs are highly dependent on IVIG dosing, hospital lengths of stay, and the number of plasma exchange days required. Conclusions: The use of IVIG for myasthenia gravis crisis may be a short-term cost minimizing therapy compared with plasma exchange. Additional prospective studies are required to evaluate the extended cost profile and efficacy of these therapies.Keywords
This publication has 17 references indexed in Scilit:
- Comparative analysis of therapeutic options used for myasthenia gravisAnnals of Neurology, 2010
- The Incidence of Myasthenia Gravis: A Systematic Literature ReviewNeuroepidemiology, 2010
- Consensus statement: The use of intravenous immunoglobulin in the treatment of neuromuscular conditions report of the aanem AD HOC committeeMuscle & Nerve, 2009
- Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitalsNeurology, 2009
- IV immunoglobulin in patients with myasthenia gravisNeurology, 2007
- The Cost Effectiveness of Anticoagulation Management Services for Patients with Atrial Fibrillation and at High Risk of Stroke in the USPharmacoEconomics, 2006
- Myasthenic crisis: Clinical features, complications and mortalityNeurology India, 2005
- The Value of Life: Estimates with Risks by Occupation and IndustryEconomic Inquiry, 2004
- Plasma exchange for generalised myasthenia gravisCochrane Database of Systematic Reviews, 2002
- Clinical trial of plasma exchange and high‐dose intravenous immunoglobulin in myasthenia gravisAnnals of Neurology, 1997